We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
Read MoreHide Full Article
Endo International plc beats on both earnings and sales in the third quarter, driven by growth in its Branded Pharmaceuticals segment as utilization of physician-administered products continues returning to pre-COVID-19 levels.
The company’s earnings of 52 cents easily beat the Zacks Consensus Estimate of 14 cents in the reported quarter but declined from the year-ago quarter’s 66 cents.
Revenues came in at $634.9 million in the quarter, surpassing the Zacks Consensus Estimate of $558 million but decreasing 13% from the year-ago quarter. The decline was attributed to lower Generic Pharmaceuticals segment’s revenues.
Endo International plc Price, Consensus and EPS Surprise
Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.
Branded Pharmaceuticals revenues were $223.6 million, up 3% year over year. Within the segment, Specialty Products revenues increased 6% to $140.1 million. Sales of Xiaflex increased 7% to $88.1 million. However, Established Products revenues decreased 2% to $83.5 million.
Sterile Injectables revenues came in at $251.4 million, down 5% year over year as a result of lower Aplisol revenues due to a nonrecurring resupply benefit witnessed in third-quarter 2019 and the ongoing competitive pressure on certain products. The decrease was somewhat offset by increased Vasostrict revenues.
Generic Pharmaceuticals reported sales of $136 million in the quarter, down 38% due to continued competitive pressure on certain key products.
International Pharmaceuticals revenues came in at $24.3 million, down 20% year over year.
During the quarter, Endo also announced a fill-finish manufacturing and services agreement for Novavax's (NVAX - Free Report) COVID-19 vaccine candidate, NVX-CoV2373.
2020 Guidance Raised
Endo raised its annual guidance. Revenues for 2020 are now projected to be $2.75-$2.80 billion, up from the earlier projected range of $2.60-$2.70 billion. Adjusted earnings per share are now estimated to be $2.50-$2.55 (previous guidance: $2-$2.15).
Our Take
Endo reported better-than-expected results for the third quarter as the Branded Pharmaceuticals segment continues to maintain momentum. Moreover, the Sterile Injectables segment performed better than management’s expectations, driven by both favorable customer purchasing patterns and higher underlying utilization of certain critical-care products.
Earlier in the year, the FDA approved QWO (collagenase clostridium histolyticum-aaes) for the treatment of moderate-to-severe cellulite in the buttocks of adult women. This should strengthen the company’s portfolio.
Concurrently, the company announced the initiation of several strategic actions to optimize its operations and increase overall efficiency.
Shares of Endo have gained 3.8% in the year so far against the industry’s 3.9% decline.
Endo’s efforts to revive its business are encouraging. The company earlier announced that it will acquire commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp. , for $88.50 per share in cash, or an estimated enterprise value of approximately $540 million.
Dr. Reddy’s earnings per share estimates have risen from $1.90 to $2.07 for 2021 and from $2.25 to $2.33 for 2022 over the past 30 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised
Endo International plc beats on both earnings and sales in the third quarter, driven by growth in its Branded Pharmaceuticals segment as utilization of physician-administered products continues returning to pre-COVID-19 levels.
The company’s earnings of 52 cents easily beat the Zacks Consensus Estimate of 14 cents in the reported quarter but declined from the year-ago quarter’s 66 cents.
Revenues came in at $634.9 million in the quarter, surpassing the Zacks Consensus Estimate of $558 million but decreasing 13% from the year-ago quarter. The decline was attributed to lower Generic Pharmaceuticals segment’s revenues.
Endo International plc Price, Consensus and EPS Surprise
Endo International plc price-consensus-eps-surprise-chart | Endo International plc Quote
Quarterly Highlights
Endo has four reportable business segments — Branded Pharmaceuticals, Generic Pharmaceuticals, Sterile Injectables and International Pharmaceuticals.
Branded Pharmaceuticals revenues were $223.6 million, up 3% year over year. Within the segment, Specialty Products revenues increased 6% to $140.1 million. Sales of Xiaflex increased 7% to $88.1 million. However, Established Products revenues decreased 2% to $83.5 million.
Sterile Injectables revenues came in at $251.4 million, down 5% year over year as a result of lower Aplisol revenues due to a nonrecurring resupply benefit witnessed in third-quarter 2019 and the ongoing competitive pressure on certain products. The decrease was somewhat offset by increased Vasostrict revenues.
Generic Pharmaceuticals reported sales of $136 million in the quarter, down 38% due to continued competitive pressure on certain key products.
International Pharmaceuticals revenues came in at $24.3 million, down 20% year over year.
During the quarter, Endo also announced a fill-finish manufacturing and services agreement for Novavax's (NVAX - Free Report) COVID-19 vaccine candidate, NVX-CoV2373.
2020 Guidance Raised
Endo raised its annual guidance. Revenues for 2020 are now projected to be $2.75-$2.80 billion, up from the earlier projected range of $2.60-$2.70 billion. Adjusted earnings per share are now estimated to be $2.50-$2.55 (previous guidance: $2-$2.15).
Our Take
Endo reported better-than-expected results for the third quarter as the Branded Pharmaceuticals segment continues to maintain momentum. Moreover, the Sterile Injectables segment performed better than management’s expectations, driven by both favorable customer purchasing patterns and higher underlying utilization of certain critical-care products.
Earlier in the year, the FDA approved QWO (collagenase clostridium histolyticum-aaes) for the treatment of moderate-to-severe cellulite in the buttocks of adult women. This should strengthen the company’s portfolio.
Concurrently, the company announced the initiation of several strategic actions to optimize its operations and increase overall efficiency.
Shares of Endo have gained 3.8% in the year so far against the industry’s 3.9% decline.
Endo’s efforts to revive its business are encouraging. The company earlier announced that it will acquire commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp. , for $88.50 per share in cash, or an estimated enterprise value of approximately $540 million.
Zacks Rank & A Stock to Consider
Endo currently carries a Zacks Rank # 2 (Buy). Another similar-ranked stock in the healthcare space is Dr. Reddy’s Laboratories Ltd (RDY - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dr. Reddy’s earnings per share estimates have risen from $1.90 to $2.07 for 2021 and from $2.25 to $2.33 for 2022 over the past 30 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>